Browsing Tag
Jeremy Bender
2 posts
Servier bets $2.5bn on pediatric cancer specialist Day One Biopharmaceuticals (Nasdaq: DAWN)
Servier is acquiring Day One Biopharmaceuticals for $2.5B to expand its rare oncology pipeline. Discover what the deal means for pediatric cancer drug innovation.
Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two…